Brief: Ascentage Pharma's Apoptosis-Targeting Drug Candidates Granted Two More Orphan Drug Designations By The Us FDA
09/10/2020 01:59
Oct 8 (Reuters) - Ascentage Pharma Group International
6855.HK :
* ASCENTAGE PHARMA'S APOPTOSIS-TARGETING DRUG CANDIDATES
GRANTED
TWO MORE ORPHAN DRUG DESIGNATIONS BY THE US FDA
Source text for Eikon: ID:nPn7qhPfma
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up